TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A U.S. judge rejected Novo Nordisk’s request to temporarily block Eli Lilly advertisements comparing the strength of their weight-loss and diabetes drugs. Separately, the FDA expanded insulin icodec’s approval, making it the first once-weekly insulin indicated for type 2 diabetes in children ages 10 and older. CDC data also showed the U.S. fertility rate fell to a record low in 2025.
A U.S. judge has rejected Novo Nordisk’s request to temporarily stop Eli Lilly from running advertisements that say its weight-loss and diabetes drugs are more powerful, while the FDA has expanded approval of once-weekly insulin icodec for people ages 10 and older with type 2 diabetes. The developments, reported in an October 27 endocrinology news roundup, come alongside CDC data showing the U.S. fertility rate fell to a record low in 2025.
The court ruling means Lilly’s challenged advertisements are not temporarily blocked by the order described in the report. The report, citing Reuters via AOL, says the ads claim Lilly’s weight-loss and diabetes drugs are more powerful; it does not provide the judge’s reasoning, the precise wording of the advertisements, or further details about the dispute. The ruling is not presented as a final decision on the underlying advertising claims.
The FDA expanded the approval for insulin icodec, sold as Awiqli, making it the first once-weekly insulin indicated for children 10 and older with type 2 diabetes, according to the roundup. The supplied report does not specify the full prescribing conditions or how the expanded indication will be implemented in clinical practice.
The roundup also reports that the U.S. fertility rate dropped 1% in 2025, to 53.2 births per 1,000 females ages 15 to 44, a record low, based on CDC data. These are separate developments rather than evidence of a connection between diabetes treatment, drug advertising and fertility trends.
Drug Ads and Pediatric Insulin
The court decision leaves Lilly’s challenged campaign running for now, keeping a high-profile comparison between competing GLP-1 and diabetes treatments in public view. Because the report gives neither the judge’s rationale nor the ads’ specific claims, readers should not treat the denial of temporary relief as a court finding that the advertisements are accurate or misleading.
The expanded Awiqli indication is relevant to families and clinicians managing type 2 diabetes in children: it adds a once-weekly insulin option to the approved treatment landscape for patients ages 10 and older. The source identifies the indication as a first, but provides no comparative evidence about outcomes, convenience, safety or uptake. The CDC fertility figures, meanwhile, are a separate population-level measure; the report does not explain the causes of the decline.
Products Worth Considering
OMRON VIVA 360+ Body Composition Monitor and Smart Scale
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
Oura Ring 4 Smart Ring – Silver – Size 8
As an affiliate, we earn on qualifying purchases.
Three Developments in One Roundup
The items appeared in MedpageToday’s October 27, 2026, endocrinology roundup, which summarized reporting and research from several outlets and journals. Its other findings included studies on prescribing patterns after American Diabetes Association guideline updates and on rising GLP-1 use among Medicare beneficiaries with type 2 diabetes. Those studies are distinct from the court dispute and FDA action.
The roundup attributes the advertising dispute to Reuters via AOL, the expanded insulin approval to the FDA, and the fertility figures to CDC data. It describes the fertility rate as the number of births per 1,000 females ages 15 to 44 and gives both the annual percentage decline and the reported rate. The source does not offer a detailed historical series or an explanation for the 2025 figure.
Details Still Missing
The available report does not say why the judge denied Novo Nordisk’s request, whether the company plans further legal action, or whether the case will proceed to a final ruling. It also does not reproduce the ads or identify the evidence each company submitted, so the substantive accuracy of the advertising claims cannot be assessed from this account.
For Awiqli, the roundup does not include the FDA’s full labeling, eligibility conditions, safety information or a timeline for availability under the expanded indication. For fertility, it provides the CDC’s headline rate and annual change but no breakdown by state, age group or other demographic characteristics, and no account of what drove the change. Those details remain outside the supplied source material.
Court and FDA Follow-Up
The next developments to watch are any further court proceedings or company statements about the advertising dispute, and the full prescribing information and clinical guidance accompanying the expanded Awiqli indication. The report does not give dates for either milestone, so no timetable can be confirmed.
Further CDC reporting may provide more detail on the 2025 fertility figures and their distribution, but the roundup does not identify a scheduled release. Until additional information is available, the confirmed points are limited to the temporary-block request’s rejection, the FDA’s expanded indication for weekly insulin icodec, and the reported national birth-rate measure.
Key Questions
What did the judge decide about Lilly’s GLP-1 advertisements?
The judge rejected Novo Nordisk’s request to temporarily block Lilly from running advertisements claiming its weight-loss and diabetes drugs are more powerful. The report does not give the judge’s reasoning or describe a final ruling on the underlying claims.
Who is covered by the expanded approval for insulin icodec?
The FDA expanded approval for insulin icodec (Awiqli) to indicate once-weekly use for people with type 2 diabetes who are ages 10 and older, according to the roundup.
What was the U.S. fertility rate in 2025?
CDC data cited in the report put the rate at 53.2 births per 1,000 females ages 15 to 44, down 1% from 2024 and described as a record low.
Are the drug-advertising case and fertility figures connected?
No connection is reported. They are separate items included in the same endocrinology news roundup.
Source: rss
